- First program to combine Recursion’s end–to–end suite of AI–enabled active learning modules, resulting in target identification to IND enabling studies in under [...] Read more »
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
MNV–201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
In pre–clinical studies, MNV–201 [...] Read more »
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today [...] Read more »
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical–stage global biopharmaceutical company committed to being a leader in the development and [...] Read more »
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical–stage global biopharmaceutical company committed to being a leader in the development and [...] Read more »
“لايفيرا أوميكس” تعيّن خبير الجينوم الكريّع رئيساً للقسم الطبي والجينومي
- لايفيرا أوميكس Read more »
Lifera Omics Appoints Prof. Fowzan Alkuraya, a Renowned Genomics Expert as Chief Medical and Genomic Officer
- Lifera, a biopharma company wholly owned by the Public Investment Fund (PIF), launched in 2023, is scaling up its subsidiary Lifera Omics and developing a team of leading Saudi and global talent to fulfil its [...] Read more »
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top–line results of the SYCAMORE trial, a [...] Read more »
Brains Bioceutical Deve Obter o Primeiro Certificado CEP do Mundo para Canabinóides, do European Directorate de Qualidade de Medicamentos e Cuidados de Saúde
SANDWICH, Reino Unido, Aug. 22, 2024 (GLOBE NEWSWIRE) — A Brains Bioceutical Corp. (BBC) alcançou um marco inovador ao fazer um dos primeiros pedidos de CEP (Certificação de Adequação) do mundo para [...] Read more »
Brains Bioceutical s’apprête à obtenir l’une des premières certifications CEP pour le cannabidiol au monde auprès de la Direction européenne de la qualité du médicament et soins de santé
SANDWICH, Royaume–Uni, 23 août 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (BBC) a franchi une étape décisive en soumettant l’une des premières demandes de CEP (Certification de [...] Read more »
Brains Bioceutical steht kurz vor Erhalt einer der weltweit ersten CEP-Zertifizierungen für Cannabidiol vom Europäischen Direktorat für die Qualität von Arzneimitteln und Gesundheitsfürsorge
SANDWICH, Vereinigtes Königreich, Aug. 23, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (BBC) hat einen bahnbrechenden Meilenstein erreicht, indem es einen der weltweit ersten CEP–Anträge (Eignungszertifikat) [...] Read more »
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare
SANDWICH, United Kingdom, Aug. 22, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (BBC) has achieved a groundbreaking milestone by submitting one of the world’s first CEP (Certification of Suitability) application for its [...] Read more »
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield
WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) — Virologist and vaccine development leader Kelly Warfield [...] Read more »
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »